Rare Cancers Act 2026: trials, data and patient access
Parliament has passed the Rare Cancers Act 2026, a new UK law aimed at speeding research and helping more people find clinical trials. It received Royal Assent on 5 March 2026, according to legislation.gov.uk, and will start to apply from early May.
Here’s the core definition. A “rare cancer” is one that affects not more than 1 in 2,000 people in the United Kingdom. That single line matters because it sets who is covered by the new research duties and who could be contacted about trials.
The first change is a system check on how cancer medicines for rare conditions are approved. The Secretary of State must review the law on marketing authorisations for ‘orphan’ cancer medicines and publish a report within three years of 5 March 2026, with a copy laid before Parliament. The review must also look at how other countries regulate similar treatments.
If you’re wondering about the jargon, an ‘orphan medicinal product’ is a medicine that meets criteria in the Human Medicines Regulations 2012 because it targets a condition affecting very few people. Think of this review as a chance to spot barriers and recommend fixes; it does not itself grant new approvals or fast-tracks.
The second change updates the NHS Act 2006. Ministers already have a duty to support research; the law now says this explicitly includes rare cancers. In practical terms, the Secretary of State must make arrangements that allow potential participants in clinical trials to be identified and contacted.
To give that work a named owner, the Act creates a National Specialty Lead for Rare Cancers. Their job description includes advising on study design and planning, and helping researchers, clinicians and patient groups work together so promising ideas do not stall between lab and clinic.
The third change is about finding people for trials more fairly and quickly. The Health and Social Care Act 2012 is amended so NHS England can disclose information from its systems to enable potential participants to be identified and contacted for relevant clinical trials, even if those trials are run outside the UK. ‘Relevant’ here means trials linked to the research and development of orphan cancer medicines.
Your privacy rights still apply. The Act states that no one may process information in a way that would breach the Data Protection Act 2018 or wider data protection law. In short, the new powers help with matching, but they do not switch off consent, confidentiality or legal safeguards.
What this means if you are a patient: you may start to hear sooner about trials that fit your diagnosis and health record. Being contacted is an invitation, not an obligation. You can ask questions, bring a family member to appointments, and say no at any point without affecting your usual NHS care.
What this means if you are a researcher or clinician: recruitment for rare cancer studies should become more feasible, with clearer routes to identify eligible patients and national advice on study design. International collaboration is built in, as trials can be supported whether or not they are hosted in the UK.
Timings and geography matter. The law takes effect two months after 5 March 2026, so changes begin in early May 2026. The research and data‑sharing measures apply in England and Wales, while the review of approval rules applies across the UK. The review report is due by 5 March 2029.
Keep an eye on three early signals: the appointment of the National Specialty Lead for Rare Cancers, NHS England’s practical guidance on how people will be identified and contacted, and the terms of reference for the approvals review. Those pieces will show how quickly this law turns into real‑world options.